Ajai Chari, MD, associate professor of medicine at the Mount Sinai School of Medicine, discusses the biggest challenge in treating patients with multiple myeloma.
The treatment landscape is very exciting, Chari says. Ten drugs have been approved over the last decade, while 4 of those were approved in 2015. However, the biggest challenge now with these patients is what happens when patients exhaust these options.
Patients who are penta-refractory are refractory to 5 of these currently approved therapies. The question is then what to do for these patients who have seemingly exhausted all options in the field, Chari concludes.
For more resources and information regarding anticancer targeted therapies in multiple myeloma: [ Ссылка ]
